The 470,000-square-foot facility will support the launch and commercial production of next-generation biologics and therapies ...

The first-quarter earnings season for the Medical sector will be in full swing this week as several drugmakers are slated to ...

Biocon Biologics secures market access agreements for Yesintek, a biosimilar to Stelara, for treating autoimmune diseases in ...

An ex-assistant U.S. attorney in Los Angeles has filed a claim calling his dismissal "unlawful" and alleging it was motivated ...

Shares of Regeneron Pharmaceuticals Inc. REGN rallied 2.65% to $605.61 Friday, on what proved to be an all-around favorable ...

Shares of Regeneron Pharmaceuticals Inc. REGN slipped 1.46% to $590.00 Thursday, on what proved to be an all-around positive ...

Robert Radick writes his first health care enforcement roundup column for the NYLJ. "This new column will, every two months, ...

Neoadjuvant immunotherapy alone resulted in significant treatment response among most patients with mismatch-repair-deficient ...

MML Investors Services ramped up its Regeneron stake by 41.7%, acquiring 2,218 additional shares during Q4. This brings their ...

Los Alamos High School junior Alyssa Sun (left) and sophomore Tate Plohr (right) received Grand Awards along with Aarush ...

Shares of Regeneron Pharmaceuticals are trading higher Wednesday recovering after a drop on Tuesday that followed the release ...

Currently, EYLEA HD is approved for dosing intervals of 8-16 weeks for patients with wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). For patients with diabetic ...